Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?  by Jamuar, Saumya Shekhar et al.
EBioMedicine 5 (2016) 211–216
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperIncidentalome from Genomic Sequencing: A Barrier to
Personalized Medicine?Saumya Shekhar Jamuar a,b, Jyn Ling Kuan c,h, Maggie Brett d, Zenia Tiang c,h, Wilson Lek Wen Tan c,h,
Jiin Ying Lim a, Wendy Kein Meng Liew a,b, Asif Javed c, Woei Kang Liew a, Hai Yang Law a,b, Ee Shien Tan a,b,
Angeline Lai a,b, Ivy Ng a,b, Yik Ying Teo e, Byrappa Venkatesh f, Bruno Reversade g, Ene Choo Tan d, Roger Foo c,h,⁎
a Department of Paediatrics, KK Women's and Children's Hospital, Singapore
b Paediatric Academic Clinical Programme, Singhealth Duke-NUS Graduate Medical School, Singapore
c Genome Institute of Singapore, A*STAR, Singapore
d KK Research Center, KK Women's and Children's Hospital, Singapore
e Saw Swee Hock School of Public Health, National University of Singapore, Singapore
f Institute of Molecular and Cell Biology, A*STAR, Singapore
g Institute of Medical Biology, A*STAR, Singapore
h Cardiovascular Research Institute, National University of Singapore, National University Health System, Singapore⁎ Corresponding author at: Cardiovascular Research In
Medicine MD6, 14 Medical Drive, National University of S
E-mail address:mdcrfsy@nus.edu.sg (R. Foo).
http://dx.doi.org/10.1016/j.ebiom.2016.01.030
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 26 November 2015
Received in revised form 16 January 2016
Accepted 25 January 2016
Available online 4 February 2016Background: InWestern cohorts, the prevalence of incidentalﬁndings (IFs) or incidentalome, referring to variants
in genes that are unrelated to the patient's primary condition, is between 0.86% and 8.8%. However, data on prev-
alence and type of IFs in Asian population is lacking.
Methods: In 2 cohorts of individuals with genomic sequencing performed in Singapore (total n = 377), we ex-
tracted and annotated variants in the 56 ACMG-recommended genes and ﬁltered these variants based on the
level of pathogenicity.We then analyzed the precise distribution of IFs, class of genes, relatedmedical conditions,
and potential clinical impact.
Results:We found a total of 41,607 variants in the 56 genes in our cohort of 377 individuals. After ﬁltering for rare
and coding variants, we identiﬁed 14 potential variants. After reviewing primary literature, only 4 out of the 14
variants were classiﬁed to be pathogenic, while an additional two variants were classiﬁed as likely pathogenic.
Overall, the cumulative prevalence of IFs (pathogenic and likely pathogenic variants) in our cohort was 1.6%.
Conclusion: The cumulative prevalence of IFs through genomic sequencing is low and the incidentalomemay not
be a signiﬁcant barrier to implementation of genomics for personalized medicine.





Incorporation of whole genome or exome sequencing (WGS/
WES), hereafter referred to as genomic sequencing, in medical prac-
tice raises the disquieting issue of incidental ﬁndings (IFs), which has
important and potentially far-reaching implications (Green et al.,
2012; Knoppers et al., 2013; Wolf et al., 2012; Roche and Berg,
2015; Hegde et al., 2015; Ayuso et al., 2015; Krier and Green,
2015). IF, also called secondary ﬁndings and occasionally referred
to as incidentalomes, are mutations in genes unrelated to the prima-
ry condition (phenotype) of the patient (Krier and Green, 2013). As
genomic sequencing is a phenotype-agnostic test, it is not surprising
that detection of IFs is of major concern and requires the decision ofstitute, Centre for Translational
ingapore, 117599, Singapore.
. This is an open access article underwhether and how return of these results to the individual should be
practiced (Krier and Green, 2013). Another concern revolves around
the additional burden this creates on the healthcare system. Individ-
uals with medically actionable IFs will require long-term surveil-
lance and anticipatory care, which is acceptable when it is
appropriate, but may be hard to justify if there is only uncorroborat-
ed evidence for the pathogenicity of the mutation in question: e.g.
even if the gene is a causal gene for the condition, the mutation
could be a novel one and never reported before for the condition.
The American College of Medical Genetics and Genomics (ACMG)
has recommended return of IFs for a minimum set of 56 actionable
genes, where prevention and surveillance may signiﬁcantly reduce
mortality and morbidity (Green et al., 2013). While these 56 genes rep-
resent rareMendelian disorders, backed by substantial years of prior re-
search and clinical experience, mutations in these genes are indeed
highly medically actionable and include well-publicized ones like
BRCA1 and BRCA2. By being classed as “medically actionable”, thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Filtering strategy.
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sures and/or treatments are available. For example, patients withmuta-
tions in cardiomyopathy-causing genes such asMYH7may have annual
electrocardiogram (ECG) and echocardiography. Individuals with path-
ogenic mutations in these genes might be asymptomatic for long
periods of time and therefore amenable to early intervention and pre-
vention to reduce mortality and long-term morbidity. Patients with
pathogenic BRCA1 and BRCA2mutations have an 80% and 45% risk of de-
veloping breast cancer, respectively (Ford et al., 1998). Identiﬁcation of
a pathogenic variant in BRCA1/BRCA2 signiﬁcantly reduces the risk of
developing breast cancer as close surveillance by an oncologist with
clinical assessment, self-examination, mammogram and/or breast MRI
allows for early detection, which, in turn leads to reduced morbidity
and improved survival (Krier and Green, 2015; Krier and Green, 2013;
Green et al., 2013; Ford et al., 1998; Warner et al., 2004). However
about 50% of women harboring BRCA1/BRCA2 mutation do not have a
family history (Loman et al., 2001) and, hence, screening for breast can-
cer may not be recommended in this group of women. Indeed the abso-
lute prevalence of breast cancer in this group of women is unclear. The
incidental identiﬁcation of individuals with these disease causing vari-
ants therefore allows the recommendation of follow-up screening offers
a net beneﬁt to individuals and society. Overall, the selection of these 56
genes may be conservative because many other genes are becoming
medically important and actionable by the month.
The European Society of Human Genetics (ESHG), on the other hand,
has recommended against using genomic sequencing in the clinic, and in-
stead recommends the use of targeted genomic tests; clearly in an effort
to avoid the scenario of unexpected IF (van El et al., 2013). However, as
the cost of genomic sequencing continues to drop, genomic sequencing
inpractice is inevitable and IFwill be clearly an issue thatwe cannot avoid.
Although with good intent, the ﬁrst issue that arises from such rec-
ommendations includes lack of data on the frequency of IFs to deter-
mine the burden on the testing laboratory as well as the referring
physician and even the healthcare system. A recent review of exome se-
quencing data from 1000 individuals (500 European and 500 African
descents) recruited in the National Heart, Blood and Lung Initiative
(NHBLI) Exome Sequencing Project (ESP) estimated the prevalence of
IFs at 3.4% for European descent and 1.2% for African descent
(Dorschner et al., 2013). A follow-up study expanded to include 6503
individuals (4300 European and 2203 African ancestry) estimated the
frequency of IFs at 1.7% for individuals of European ancestry and 1.0%
for African ancestry (Amendola et al., 2015). In unrelated cohorts, IFs
were detected in 8.8% of the participants recruited through National In-
stitute of Health Undiagnosed Disease Program (n = 543) (Lawrence
et al., 2014), 0.86% in the Baylor-Hopkins Center for Mendelian Geno-
mics (n = 232) (Jurgens et al., 2015), and 1.9% in the UK WGS500 co-
hort (n = 500) (Taylor et al., 2015). Within Asia, a review of 196
Korean exomes detected IFs in 7% of control subjects (n = 100) and
6% of patients with disease (n = 96) (Jang et al., 2015). Although
Singapore is a nation gearing up for genomics (Manolio et al., 2015),
such data is lacking for an Asian population and hence, there are no pol-
icies and recommendations regarding IFs in Singapore. In this study, we
set out to estimate the prevalence as well as deﬁne the types of IFs
found in genomic sequencing that was performed in 2 cohorts of the
Asian population in Singapore. Singapore, as an island country in
South East Asia, is uniquely dominated by immigrant ethnic groups,
comprising Chinese, Malays, and Indians. The IF analysis from our
study should hence be representative of the proﬁle in South East Asia.
2. Methods
2.1. Patient Recruitment
Individuals were recruited through institutional ethics review board
approved genomics projects. Informed consent was obtained from the el-
igible individual (or parent/legal guardian, when the individual is aminor). Sequencing data of these individuals was anonymized, de-
identiﬁed and analyzed in a cumulative manner.2.2. Genomic Sequencing
Blood samples were obtained from the consented individuals and
DNA was extracted by established methods. Samples were sequenced
on HiSeq 2000/HiSeq 2500 or Ion Proton using established protocols.
Data generated from genomic sequencing were aligned to the human
reference genome using established bioinformatic algorithms and soft-
ware (e.g. BWA-MEM followed by SAMtools to generate SAM/BAM
ﬁles) (Li and Durbin, 2009). BAM ﬁles were processed using GATK
(DePristo et al., 2011) to generate variant calling format (VCF) ﬁles.2.3. Gene List Development
The list of genes we chose to analyze was conﬁned to the 56 action-
able genes recommended by ACMG (Supplementary Table 1) (Green
et al., 2013). These genes were selected on the basis that deleterious
variants would lead to speciﬁc conditions of high disease penetrance,
for which evidence-based medical recommendations are available, im-
plementation of which would arguably help towards preventing signif-
icant morbidity and mortality.2.4. Bioinformatic Filtering
Variants were quality ﬁltered to exclude false positives according to
standard thresholds (Quality scores N30, coverage N10×, and absence
of clustered variantswithin awindow size of 10 variants). Fromvariants
that passed this threshold, we extracted variants in each of the 56 genes
in our gene list (Appendix 1) (Green et al., 2013). We then annotated
the variants using our in-house bioinformatic pipeline to include infor-
mation regarding the gene, chromosomal coordinate(s), genetic
change, protein change, type of mutation (frameshift, nonsense,
nonsynonymous, splicing, and synonymous); prediction of the variant
from multiple algorithms (Polyphen-2, Adzhubei et al., 2013, SIFT, Ng
and Henikoff, 2003, likelihood ratio test and MutationTaster2, Schwarz
et al., 2014), allele frequencies in different databases (Exome Sequenc-
ing Project, dbSNP, 1000 Genomes, Complete Genomics, Exome Aggre-
gation Consortium, and our in-house database of common variants
(present in N5% of the population)), and annotation of variants in clini-
cal mutation databases like Clinvar (http://www.ncbi.nlm.nih.gov/
clinvar/), and Human Genetic Mutation Database (http://www.hgmd.
cf.ac.uk/ac/index.php) (Fig. 1). We then further analyzed the variant
as per our ﬁltering strategy illustrated in Fig. 1.
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Given that we are addressing IFs, we used stringent criteria for the
classiﬁcation of the variants to avoid false positives. Although certain
mutations listed in the clinical mutation databases have been listed as
pathogenic, the evidence for pathogenicity of some of these variants
may be lacking (McLaughlin et al., 2014; Richards et al., 2015). Hence,
we reviewed the primary literature regarding each of the ﬁltered vari-
ants and reclassiﬁed them as per Table 1.
2.6. Quality Control
We bioinformatically reviewed the sequence aligned read of each of
the samples to ensure that all exons and intron-exon junction of the 56
geneswere adequately covered by the genomic sequencing.We exclud-
ed samples in which the genes were inadequately covered so as to re-
duce false negatives, which would underestimate the frequency of IFs.
2.7. Funding
Saumya Shekhar Jamuar is supported by the National Medical Re-
search Council and Nurturing Clinician Scientist Scheme, Singhealth
Duke-NUS Academic Clinical Programme. Roger Foo is funded by the
National Medical Research Council and Biomedical Research Council,
Agency for Science, Research and Technology (A*STAR). Bruno
Reversade is a fellow of the BrancoWeiss Foundation, an A*STAR Inves-
tigator, and a Young EMBO Investigator. This workwas partly funded by
the Sequencing Congenital Disorders in Singapore project (seqCDS) and
a Strategic Positioning Fund on Genetic Orphan Diseases from A*STAR,
Singapore. The funders did not play any role in the design of the
study, in the drafting of the manuscript or decision to submit for
publication.
3. Results
3.1. Characteristics of the Participants
Individuals were recruited from 2 diverse cohorts of participants
(Table 2). The ﬁrst cohort (n = 245) comprised of individuals and
their biological parents undergoing genomic sequencing to investigate
the underlying genetic etiology of the individual's multiple congenital
anomalies, developmental delay and/or intellectual disability. Genomic
data from the proband as well as their family members was included in
the analysis. However, a variant identiﬁed in related individuals was
counted as one to avoid double counting of familial variants. The secondTable 1
Variant classiﬁcation criteria.
1. Pathogenic:
1.1. Allele frequency of variant below the disease speciﬁc prevalence, AND
1.2. Segregation in at least two unrelated families, OR
1.3. Segregation in one family and identiﬁed in at least three unrelated affected
individuals, OR
1.4. Protein truncation where this event is known to cause disease, OR
1.5. Functionally characterized variant
2. Likely pathogenic:
2.1. Allele frequency of variant below the disease speciﬁc prevalence, AND
2.2. Identiﬁed in at least three unrelated individuals, OR
2.3. Segregation in one family, OR
2.4. At least one de novo event in trio
3. Variant of uncertain signiﬁcance:
3.1. Allele frequency of variant below the disease speciﬁc prevalence, AND
3.2. Identiﬁed in fewer than three unrelated affected individuals, OR
3.3. No segregation studies, OR
3.4. No de novo event in a trio
4. Likely benign
4.1. Allele frequency of variant above the disease speciﬁc prevalence, AND/OR
4.2. Seen in combination with a known pathogenic mutationcohort (n = 138) comprised of adults who underwent genomic se-
quencing for population based studies and were reportedly healthy.
Six of the samples did not fulﬁll QC criteria and were excluded from
this analysis. Details of the second cohort have been published previous-
ly (Wong et al., 2013, 2014). Individuals in cohort one were given the
option regarding return of IFs. Eighty-three percent opted for the return
of such results.
3.2. Characteristics of Variants
In the ﬁrst cohort, we identiﬁed 1381 variants in the 56 genes
(Table 3). After excluding common variants, we found 6 variants that
were reportedly pathogenic mutations according to Clinvar and/or
HGMD. In the second cohort, we identiﬁed 40,226 variants in the 56
genes. As this cohort had undergone whole genome sequencing, the
majority of these variants were in the non-coding region of the 56
genes. After ﬁltering for coding and rare variants, we identiﬁed 5 vari-
ants that were reportedly pathogenic according to Clinvar and/or
HGMD. As these mutation databases are biased against non-Caucasian
population (Dorschner et al., 2013), we further analyzed for novel pro-
tein truncating mutations (stopgain, stoploss, frameshift, indels) in
these 56 genes, and found three additional variants (one in cohort 1
and two in cohort 2). None of these variants were detected in more
than one individual.
3.3. Variant Reclassiﬁcation Based on Primary Literature
Out of the 14 pathogenic variants, two of the variants were in genes
(MUTYH and PCSK9)where diseasemanifests in the presence of biallelic
mutations and hence, detection of monoallelic variants in these genes
was considered to be non-disease causing. Of the remaining 12 variants,
we reviewed the primary literature for each of the variant and
reclassiﬁed them as per our criteria (Table 4). Only four of the 12 vari-
ants were classiﬁed as pathogenic — two in SCN5A (associated with
Brugada syndrome, OMIM: 601144), and one each in BRCA2 (associated
with hereditary breast and ovarian cancer, OMIM: 612555), and TP53
(associated with Li-Fraumeni syndrome; OMIM: 151623) (Table 2);
while an additional two variants were classiﬁed as likely pathogenic.
Both were truncating mutations, one each in TNNT2 (associated with
cardiomyopathy, OMIM: 601494), and COL3A1 (associated with Ehlers
Danlos syndrome, vascular type, OMIM: 130050). The remaining
six variants were classiﬁed as “variant of unknown signiﬁcance” (VUS)
(4 variants) and likely benign (2 variants) (Table 4). Overall, the cumu-
lative prevalence of pathogenic IFs in our cohort of 377 individuals was
1.1%. After including likely pathogenic IFs, the estimated prevalence
was 1.6%.
4. Discussion
Sequencing of the ﬁrst human genome took more than a decade,
completing in 2001, and costing more than US$2.7 million (Lander
et al., 2001; Venter et al., 2001;NHGRI, 2010). In the subsequent decade,
newer high-throughput genomic technologies, known as the Next-
Generation sequencing technologies, have been able to sequence and
detect genetic variation in humans with high levels of accuracy, at
breakneck speeds and at a fraction of that cost: offering the promise of
fundamentally changingmedical practice and ﬁnally delivering person-
alized medicine (Manolio et al., 2013; Mayer et al., 2011). Next-genera-
tion clinical genomics has potential to transform healthcare by bringing
us closer to delivering optimal treatment, prescribed based on an
individual's genetic proﬁle.
With improvement in genomic technologies, our ability to collect,
analyze and aggregate data from large-scale sequencing continues to
expand. The complexity of results generated from genomic sequencing
thus presents unique challenges to clinicians, patients and their families
in the areas of informed consent, genetic counseling and return of
Table 2
Participant characteristics.
Study cohort Type of genomic sequencing Sample size Sample size after QC Ethnicity
Chinese Malay Indian Others
Cohort 1 WES 245 245 182 10 25 28
Cohort 2 WGS 138 132 0 96 36 0
Total 383 377 182 106 61 28
WES: Whole exome sequencing, WGS: Whole genome sequencing.
214 S.S. Jamuar et al. / EBioMedicine 5 (2016) 211–216results (Green et al., 2012; Wolf et al., 2012; Roche and Berg, 2015;
Hegde et al., 2015; Krier and Green, 2015; Burke et al., 2013;
Kleiderman et al., 2014; Yu et al., 2014a, 2014b). There aremany aspects
requiring clarity and attention. Patients will need to understand the im-
plications of pathogenic mutations, and what it means for family mem-
bers whomay be carriers of themutation. Referring clinicians will need
to understand that not all mutations (more accurately called variants)
are necessarily pathogenic although they may occur in disease causing
genes. Genetic counseling will need to address issues of possible patho-
genic variants, variants of unknown signiﬁcance, di-genic ormulti-genic
inheritance, and disease penetrance. After clarifying the implications
from results in genes related to the primary condition, we are then
faced with the equally, if not more challenging issue of variants in
other “medically important” genes, that may be unrelated to the
patient's primary medical condition or that may be confounded by
one's ethnicity. In our busy and time-constrained health care systems,
explaining the complexities of the genomic sequencing process is a
challenge and will need deliberate effort to address. We anticipate an
increase in the use of genomics in clinics in the coming years, some of
which may be driven by well-informed patients themselves or by com-
mercial entities. There is undoubtedly an urgent need for recommenda-
tions and a build-up of reliable experience.
Detection of IFs has implications not only for the individual, but also
his/her familymembers (McLaughlin et al., 2014). For example,WES on
a patient with intellectual disability may detect pathogenic variants in
BRCA1. This mutation could be inherited from the parents, which
means that the affected parent (and his/her siblings) is at risk of devel-
oping cancer and would require surveillance andmonitoring. This fam-
ily may or may not be prepared to receive such information and this
issue needs to be discussed during the informed consent process.
While the Genetic Information Non-discrimination Act (GINA 2008) in
USA offers protection to individuals against discrimination for health in-
surance and employment based on their genetic information, it is not
comprehensive and excludes life insurance; and similar laws are lacking
in other countries (Dorschner et al., 2013). Indeed individualswith a ge-
netic diagnosis, especially those with incidental ﬁndings, may face dis-
crimination at work or be denied of medical insurance without any
avenue for legal redress.
Our study detected a combined prevalence of IFs at 1.6% among a
representative South East Asian population,which is similar to the prev-
alence in other ethnic groups and is consistent with the rates of preva-
lence of these disorders. In addition, a majority of individuals (83%)Table 3
Filtering strategy and variants detected in the study cohorts.







Total number of variants in 56 genes 1381 40,226 41,607
Exclude “common” SNPsa 768 14,447 15,215
Exclude “non-exonic” SNPsb 523 435 958
Include “pathogenic” SNPsc 6 5 11
a Common SNPs deﬁned as present in N5% of population.
b Intronic, intergenic, non-coding, upstream, downstream.
c Deﬁned as pathogenic in Clinvar and/or HGMD.responded favorably to the return of IFs, which highlights the impor-
tance of including the patient in the decision making process. Four of
the 6 variants are in cardiac-related genes (SCN5A, TNNT2 and
COL3A1). Mutations in SCN5A and TNNT2 are associated with Brugada
syndrome and cardiomyopathy, respectively, and can presentwith sud-
den death as their ﬁrst presentation. Detection of carrier status for the
mutations allows for anticipatory guidance in the form of regular elec-
trocardiogram and echocardiography, and avoidance of triggers such
as certain medications like macrolides. These measures can avert the
usual catastrophic presentation of these disorders (Priori et al., 2013).
In addition, cascade screening of family members can identify other
at-risk individuals who can then be managed accordingly (Priori et al.,
2013). Similarly, guidelines and recommendations exist for patients
withmutations in BRCA2, TP53, and COL3A1which allows for anticipato-
ry management and minimizes mortality and long-term morbidity
(Warner et al., 2004; Ballinger et al., 2015; Lum et al., 2011). These re-
sults suggest that comprehensiveness of WES/WGS tests should be ex-
plained to the interested patients and treated as an opportunity to
provide important health information.
While we studied the prevalence of variants in highly actionable
genes, we did not include genes in which mutations could lead to con-
ditionswhere no therapy exists tomanage the consequences of the del-
eterious mutation (Berg et al., 2011) (e.g. Huntington disease, Prion
disease or frontotemporal dementia), i.e. results that are “not-action-
able”. The list also does not include rare diseases where less knowledge
is available about their level of penetrance (Berg et al., 2011) (e.g. APOE4
allele and Alzheimer disease risk), or where individuals may in fact only
be carriers of these recessive conditions (e.g. thalassemia, cystic ﬁbro-
sis). There are also variants in pharmacogenetic-relevant genes which
may not be disease causing, but could have clinically meaningful infor-
mation for future management of the patient (e.g. CYP2CP and VKORC1
single nucleotide polymorphisms and warfarin dosing) (Grossniklaus,
2010). As our understanding of each of these contexts improves, the
list of “actionable” genes and their potential burden on the healthcare
system may increase with time.
In conclusion, genomic sequencing is rapidly moving into medical
practice. The scope of understanding and interpreting genomic se-
quencing is imperative in context of the patient's primary condition,
but contemporaneously uncovered incidental mutations (or variants)
in medically actionable genes not related to the primary condition will
also need attention. The data presented here helps to improve our un-
derstanding of the nuances relating to implementation of clinical geno-
mics as we pursue precision medicine on all fronts and is anticipated to
beneﬁt national policymakers as well as medical bodies as they discuss,
debate and formulate recommendations for clinical genomic testing.
Given the net beneﬁt to the individual and society and relatively low
burden of IFs, efforts to develop effective processes for separating and
reporting only serious disease causing ﬁndings with necessary educa-
tion should be treated as an opportunity and not as a burden.




Classiﬁcation of variants based on review of primary literature.
Gene name Variant (hg19) Primary associated condition (OMIM #) Amino acid change dbSNP ID Ethnicity
Pathogenic
SCN5A chr3:38645439CNG;het Long QT syndrome, Brugada syndrome (#601144) p.Gly552Arg rs3918389 Chinese
SCN5A chr3:38592986CNT;het Long QT syndrome, Brugada syndrome (#601144) p.Arg1625Pro rs199473283 Chinese
BRCA2 chr13:32915033GNT;het Hereditary breast and ovarian cancer (#612555) p.Gly2181* rs371067421 Malay
TP53 chr17:7577094GNA;het Li-Fraumeni syndrome (#151623) p.Arg282Trp rs28934574 Chinese
Likely pathogenic
TNNT2 chr1:201332522GNA;het Hypertrophic and/or dilated cardiomyopathy (#601494) p.Arg158* NA Chinese
COL3A1 chr2:189861145CNT;het Ehlers Danlos syndrome, vascular type (#130050) p.Arg562* rs375737772 Malay
Variants of uncertain signiﬁcance
SCN5A chr3:38592386CNT;het Long QT syndrome, Brugada syndrome (#601144) p.Arg1826His rs137854610 Chinese
SCN5A chr3:38640472CNT;het Long QT syndrome, Brugada syndrome (#601144) p.Glu654Lys rs199473138 Others
SCN5A chr3:38622640ANG;het Long QT syndrome, Brugada syndrome (#601144) p.Cys1004Arg rs199473183 Indian
FBN1 chr15:48888525GNC;het Marfan syndrome (#154700) p.Arg165Gly rs113905529 Malay
Likely benign
RET chr10:43601830GNA;het Multiple endocrine neoplasia type 2 (#171400) p.Val292Met rs34682185 Chinese
BRCA2 chr13:32972626ANT;het Hereditary breast and ovarian cancer (#612555) p.Lys3326* rs11571833 Indian
Exclude
MUTYH chr1:45797760TNC;het MYH associated polyposis (#132600) c.934-2ANG rs77542170 Malay
PCSK9 chr1:55527110CNT;het Familial hypercholesterolemia
(#603776)
p.Arg289* rs373323910 Malay
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